We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Sanoculis Stock

Invest in or calculate the value of your shares in Sanoculis or other pre-IPO companies through EquityZen's platform.

Get Started

Sanoculis Stock (SANC)

Sanoculis is a medical device start-up company that develops an innovative surgical procedure for the treatment of the Glaucoma.

About Sanoculis Stock

Founded

2012

Industries

Software, Data and Analytics, Artificial Intelligence

Sanoculis is a medical device start-up company that develops an innovative surgical procedure for the treatment of the Glaucoma. The company offers a new alternative surgical procedure for treating glaucoma. Its Minimally Invasive Micro Sclerostomy (MIMS) solution consists of a single-patient-use sterile tool and a multi-use external machine. In the course of the surgery, a sclero-corneal drainage channel is created to reduce intraocular pressure. MIMS is a microfluidic full-thickness procedure developed as an advanced laser sclerotomy. The technique uses a cutting and drilling device to reduce trauma to the surrounding tissue, minimizing scar tissue formation and allowing for a long-lasting filtering bleb. The MIMS channel ensures a controlled fluid flow with minor complications. The company was founded in 2012 and is based in Tel Aviv, Israel

Sanoculis Press Mentions

Stay in the know about the latest news on Sanoculis

Sanoculis Management

Leadership team at Sanoculis

Co-Founder and CEO

Nir Israeli

Medical Director and Co-Founder

Yoseph Glovinsky

Locked Features

Join now and verify your accreditation status to gain access to:

  • Sanoculis current valuation
  • Sanoculis stock price
  • Available deals in Sanoculis and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Sanoculis stock?

Accredited investors can buy pre-IPO stock in companies like Sanoculis through EquityZen funds. These investments are made available by existing Sanoculis shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Sanoculis stock?

Shareholders can sell their Sanoculis stock through EquityZen's private company marketplace. EquityZen's network includes over 320K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 42K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."